Your session is about to expire
← Back to Search
Other
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) (MVOR-2 Trial)
Phase 3
Waitlist Available
Research Sponsored by Journey Medical Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 16
Awards & highlights
Pivotal Trial
Summary
This trial is testing two types of pills, DFD-29 and Doxycycline, in adults with moderate to severe rosacea. The goal is to see which treatment best reduces redness and bumps by lowering inflammation or killing bacteria. Doxycycline has been widely used for its anti-inflammatory properties.
Eligible Conditions
- Papulopustular Rosacea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to week 16
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 16
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Total Inflammatory Lesion Count Compared to Placebo.
Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.
Secondary study objectives
Change in Total Inflammatory Lesion Count Compared to Doxycycline.
Clinician's Erythema Assessment (CEA) Change Compared to Placebo.
Doxycycline
Side effects data
From 2023 Phase 3 trial • 323 Patients • NCT052966293%
COVID-19
3%
Nasopharyngitis
2%
Vulvovaginal mycotic infections
2%
Diarrhea
2%
Headache
1%
Dry Skin
1%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
DFD-29
Placebo
Doxycycline 40 mg
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: DFD-29Experimental Treatment1 Intervention
DFD-29 (40 mg) extended release capsules
Group II: Doxycycline 40 mgActive Control1 Intervention
Doxycycline 40 mg modified release capsules
Group III: PlaceboPlacebo Group1 Intervention
Placebo capsules matching DFD-29
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DFD-29
2022
Completed Phase 3
~660
Find a Location
Who is running the clinical trial?
Journey Medical CorporationLead Sponsor
9 Previous Clinical Trials
2,043 Total Patients Enrolled
Dr. Reddy's Laboratories LimitedIndustry Sponsor
235 Previous Clinical Trials
47,157 Total Patients Enrolled
Srinivas R Sidgiddi, M.D.Study DirectorJourney Medical Corporation
2 Previous Clinical Trials
347 Total Patients Enrolled